Discovery

Mediar Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Distributed Bio Partners With Mediar Therapeutics, Inc.

Lead Product(s): Neutralizing antibodies

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Distributed Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 03, 2020

Details:

Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.

Axonis Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy

Lead Product(s): KCC2

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Kerry Murphy

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing May 28, 2020

Details:

The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.

WuXi Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

Lead Product(s): Bispecific antibodies

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Aravive

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 30, 2020

Details:

Collaboration grants Aravive the right to use the proprietary WuXiBody™ platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Mediar Therapeutics

Distributed Bio Partners With Mediar Therapeutics, Inc.

Axonis Therapeutics

AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy

WuXi Biologics

WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform